In Vitro Diagnostics Quality Control Market Leading Players and Business Strategies
According to research report the global In Vitro Diagnostics Quality Control Market is projected to reach USD 1,158 million by 2025 from USD 961 million in 2020, at a CAGR of 3.8% during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198032582
Key
players are focusing on increasing their presence in this growing
market through both organic as well as inorganic growth strategies, such
as product launches, agreements, partnerships, collaborations, and
expansions. Due to the intense competition in the In Vitro Diagnostics
Quality Control Market, various market players are increasingly focusing
on expanding their geographic presence in high-growth emerging markets.
Bio-Rad
Laboratories Inc. (US) was the leading player in the In Vitro
Diagnostics Quality Control Market and accounted for the largest share
in 2018. The company is a leading provider of clinical diagnostic
systems, analytical devices, and instruments. The company has a robust
portfolio of quality control products, data management solutions and
quality assurance services for hospital laboratories, reference
laboratories, transfusion laboratories, and physician office
laboratories. Bio-Rad Laboratories’ position in the market can be
attributed to its strong distribution network and its subsidiaries
across the globe, which enables it to serve customers in North America,
Europe, and the Asia Pacific. To garner a large share of the IVD quality
control market, the company continuously focuses on organic and
inorganic growth strategies. For instance, in May 2019, the company
launched InteliQ and Load-and-Go Tubes for quality controls to
streamline the laboratory workflow. With this new launch the company
enabled to strengthen its chemistry and immunoassay quality controls
offerings.
Randox Laboratories Ltd. (UK) held the second-largest
share of the global IVD quality control market. Its position in the
market can be attributed to its robust product portfolio and a strong
network of partners across the world. Under its flagship brands
‘Acusera’ and ‘RIQAS,’ the company offers various quality controls and
EQA schemes across the globe. To maintain its position in the market,
the company focuses on expanding its product portfolio through
strategies, such as product launches and expansions. For instance, in
August 2019, the company launched multi-analyte Acusera infectious
disease (serology) control for the analysis of infectious diseases.
The
North America is expected to account for the largest share of the
global In Vitro Diagnostics Quality Control Market in 2020, followed by
Europe. The large share of the North America can be attributed to the
highly developed healthcare system in the US and Canada, and the
presence of a large number of leading IVD quality control vendors &
national clinical laboratories & hospitals in this region.
Request Free Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=198032582
Comments
Post a Comment